Evidence map›Paper›PMID 35396591›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size.

Thomas A Rasmussen, Sunil K Ahuja, Locadiah Kuwanda, Michael J Vjecha, Fleur Hudson, Luxshimi Lal, Ajantha Rhodes, Judy Chang, Sarah Palmer, Paula Auberson-Munderi and 18 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 18 institutions in 9 countries.

Thomas A RasmussenDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Sunil K AhujaDepartment of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA.
Locadiah KuwandaThe Kirby Institute, University of New South Wales, Sydney, Australia.
Michael J VjechaInstitute for Clinical Research, Inc., Veterans Affairs Medical Center, Washington D.C., USA.
Fleur HudsonMRC Clinical Trials Unit at UCL, London UK Uganda Virus Research Institute/MRC, London, United Kingdom.
Luxshimi LalBurnet Institute, MelbourneAustralia.
Ajantha RhodesDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Judy ChangDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Sarah PalmerCentre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Paula Auberson-MunderiUNAIDS, HIV Prevention, Geneva, Switzerland.
Henry MugerwaJoint Clinical Research Centre, Entebbe, Uganda.
Robin WoodThe Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Sharlaa Badal-FaesenClinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Sandy PillayEnhancing Care Foundation, Department of Research and Post-graduate Support, Durban University of Technology, Durban, South Africa.
Rosie MngqibisaEnhancing Care Foundation, Department of Research and Post-graduate Support, Durban University of Technology, Durban, South Africa.
Alberto LaRosaAsociación Civil Impacta Salud y Educación, Lima, Perú.
Jose HildagoVia Libre, Lima, Perú.
Kathy PetoumenosThe Kirby Institute, University of New South Wales, Sydney, Australia.
Chris ChiuDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Joseph LutaakomeLSHTM Uganda Research Unit, HIV Intervention Programme, Entebbe, Uganda.
Jonathan KitonsaLSHTM Uganda Research Unit, HIV Intervention Programme, Entebbe, Uganda.
Esther KabaswagaJoint Clinical Research Centre, Entebbe, Uganda.
Pietro PalaImmunova Limited, London, United Kingdom.
Carmela GanozaAsociación Civil Impacta Salud y Educación, Lima, Perú.
Katie FisherCentre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Christina ChangThe Kirby Institute, University of New South Wales, Sydney, Australia.
Sharon R LewinDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Edwina J WrightDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
University of Melbourne · AUAsociación Civil Impacta Salud y Educación · PEDurban University of Technology · ZAJoint Clinical Research Centre · UGMonash University · AUUganda Virus Research Institute · UGUNSW Sydney · AUAarhus University Hospital · DKBurnet Institute · AUFundación Vía Libre · ARJoint United Nations Programme on HIV/AIDS · CHPeter Doherty Institute · AUThe University of Texas Health Science Center at San Antonio · USUniversity College London · GBUniversity of Cape Town · ZAUniversity of Sydney · AUUniversity of the Witwatersrand · ZAWestmead Institute for Medical Research · AU

Funding

Extended follow-up of randomized participants in the INSIGHT START trialU01AI136780 · NIAID · UNIVERSITY OF MINNESOTA · PI GRUND, BIRGIT, REILLY, CAVAN S. · 2019 to 2024
$18.0M
NIAID NIH HHS U01 AI136780
6 · The paper itself

Abstract

backgroundIdentifying factors that determine the frequency of latently infected CD4+ T cells on antiretroviral therapy (ART) may inform strategies for human immunodeficiency virus (HIV) cure. We investigated the role of CD4+ count at ART initiation for HIV persistence on ART.

methodsAmong participants of the Strategic Timing of Antiretroviral Treatment Study, we enrolled people with HIV (PWH) who initiated ART with CD4+ T-cell counts of 500-599, 600-799, or ≥ 800 cells/mm3. After 36-44 months on ART, the levels of total HIV-DNA, cell-associated unspliced HIV-RNA (CA-US HIV-RNA), and two-long terminal repeat HIV-DNA in CD4+ T cells were quantified and plasma HIV-RNA was measured by single-copy assay. We measured T-cell expression of Human Leucocyte Antigen-DR Isotype (HLA-DR), programmed death-1, and phosphorylated signal transducer and activator of transcription-5 (pSTAT5). Virological and immunological measures were compared across CD4+ strata.

resultsWe enrolled 146 PWH, 36 in the 500-599, 60 in the 600-799, and 50 in the ≥ 800 CD4 strata. After 36-44 months of ART, total HIV-DNA, plasma HIV-RNA, and HLA-DR expression were significantly lower in PWH with CD4+ T-cell count ≥ 800 cells/mm3 at ART initiation compared with 600-799 or 500-599 cells/mm3. The median level of HIV-DNA after 36-44 months of ART was lower by 75% in participants initiating ART with ≥ 800 vs 500-599 cells/mm3 (median [interquartile range]: 16.3 [7.0-117.6] vs 68.4 [13.7-213.1] copies/million cells, respectively). Higher pSTAT5 expression significantly correlated with lower levels of HIV-DNA and CA-US HIV-RNA. Virological measures were significantly lower in females.

conclusionsInitiating ART with a CD4+ count ≥ 800 cells/mm3 compared with 600-799 or 500-599 cells/mm3 was associated with achieving a substantially smaller HIV reservoir on ART.

Indexed as

Anti-Retroviral AgentsHIV InfectionsCD4 Lymphocyte CountCD4-Positive T-LymphocytesFemaleHIVHLA-DR AntigensHumansRNAViral LoadAnti-Retroviral AgentsHLA-DR AntigensRNAantiretroviral therapyHIVHIV cureHIV reservoir

Identifiers

PMID35396591
PMCPMC9662177
OpenAlexW4223517032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.